Reuters FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to ...
On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...
Merck said its “once-in-a-lifetime” drug Keytruda could be subject to price reductions under the Inflation Reduction Act, which would lead to a … ...
Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...
HYDERABAD, India (Reuters) - Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the year, a senior company ...
HYDERABAD, India (Reuters) - Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the year, a senior company executive ...
Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...
Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...
Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback